Phase 1 trial

NEWARK, Calif., June 8, 2026 Corsair Pharma, Inc. announced three presentations showcasing positive Phase 1 clinical data for its...

COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...

AUSTIN, Texas and DURHAM, N.C., June 5, 2026 Shattuck Labs announced that it will host an investor call and...

WELLESLEY HILLS, Mass., June 5, 2026 Climb Bio, Inc. announced the presentation of initial Phase 1 safety data and...

SAN CARLOS, Calif., June 2, 2026 Vaxcyte, Inc. announced that the first participant has been dosed in a Phase...

WALTHAM, Massachusetts, USA, June 2, 202 Stelexis BioSciences has announced encouraging Phase 1 clinical trial results for eganelisib, its...

SAN DIEGO, Calif., June 1, 2026 Avenzo Therapeutics announced updated clinical results from the Phase 1 portion of its...

REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...

NEWARK, Calif., June 1, 2026 Protagonist Therapeutics announced that four abstracts featuring rusfertide in polycythemia vera (PV) will be...

Edinburgh, UK | May 28, 2026 Clinical-stage oncology company Trogenix announced the first patient has been dosed in the...